Aegis Reaffirms Buy Rating for China Biologic Products (CBPO)
China Biologic Products (NASDAQ:CBPO)‘s stock had its “buy” rating reaffirmed by analysts at Aegis in a research report issued to clients and investors on Wednesday. They currently have a $59.00 price target on the stock, up from their previous price target of $55.00. Aegis’ price objective points to a potential upside of 10.18% from the stock’s previous close.
Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of China Biologic Products in a research note on Thursday, July 24th. They now have a $57.00 price target on the stock, up previously from $52.00.
China Biologic Products (NASDAQ:CBPO) traded down 0.30% during mid-day trading on Wednesday, hitting $53.3887. The stock had a trading volume of 13,585 shares. China Biologic Products has a 52-week low of $23.79 and a 52-week high of $58.00. The stock’s 50-day moving average is $47.16 and its 200-day moving average is $41.68. The company has a market cap of $1.307 billion and a P/E ratio of 23.32.
China Biologic Products, Inc (NASDAQ:CBPO) is a biopharmaceutical company.
Receive News & Ratings for China Biologic Products Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.